Cyclooxygenase-2 expression in hamster and human pancreatic neoplasia

Pamela L. Crowell, C. Schmidt, Michele Yip-Schneider, Jesse J. Savage, Dean A. Hertzler, Oscar Cummings

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Cyclooxygenase-2 (COX-2) has been implicated in the development of gastrointestinal malignancies. The aim of the present study was to determine COX-2 expression/activity throughout stages of experimental and human pancreatic neoplasia. COX-2 immunohistochemistry was performed in pancreata of hamsters subjected to the carcinogen N-nitrosobis-(2-oxopropyl) amine (BOP) and in human pancreatic tumors. COX-2 activity was determined by prostaglandin E2 assay in tumor versus matched normal pancreatic tissues. The activity of the COX inhibitor sulindac was tested in the PC-1 hamster pancreatic cancer model. COX-2 expression was elevated in all pancreatic intraepithelial neoplasias (PanINs) and adenocarcinomas. In BOP-treated hamsters, there were significant progressive elevations in COX-2 expression throughout pancreatic tumorigenesis. In human samples, peak COX-2 expression occurred in PanIN2 lesions and remained moderately elevated in PanIN3 and adenocarcinoma tissues. COX-2 activity was significantly elevated in hamster and human pancreatic cancers compared to pair-matched normal pancreas. Furthermore, hamster pancreatic tumor engraftment/formation in the PC-1 hamster pancreatic cancer model was reduced 4.9-fold by oral administration of sulindac. Increased COX-2 expression is an early event in pancreatic carcinogeneses. The BOP-induced hamster carcinogenesis model is a representative model used to study the role of COX-2 in well-differentiated pancreatic tumorigenesis. COX inhibitors may have a role in preventing tumor engraftment/formation.

Original languageEnglish
Pages (from-to)437-445
Number of pages9
JournalNeoplasia
Volume8
Issue number6
DOIs
StatePublished - 2006

Fingerprint

Cyclooxygenase 2
Cricetinae
Neoplasms
Carcinogenesis
Pancreatic Neoplasms
Sulindac
nitrosobis(2-oxopropyl)amine
Pancreas
Dinoprostone
Carcinogens
Oral Administration
Adenocarcinoma
Immunohistochemistry

Keywords

  • Chemical carcinogenesis
  • COX-2
  • Pancreatic neoplasms
  • PanIN
  • Sulindac

ASJC Scopus subject areas

  • Cancer Research

Cite this

Cyclooxygenase-2 expression in hamster and human pancreatic neoplasia. / Crowell, Pamela L.; Schmidt, C.; Yip-Schneider, Michele; Savage, Jesse J.; Hertzler, Dean A.; Cummings, Oscar.

In: Neoplasia, Vol. 8, No. 6, 2006, p. 437-445.

Research output: Contribution to journalArticle

Crowell, Pamela L. ; Schmidt, C. ; Yip-Schneider, Michele ; Savage, Jesse J. ; Hertzler, Dean A. ; Cummings, Oscar. / Cyclooxygenase-2 expression in hamster and human pancreatic neoplasia. In: Neoplasia. 2006 ; Vol. 8, No. 6. pp. 437-445.
@article{702ec93bc00e4fa386a44ff31ebaac33,
title = "Cyclooxygenase-2 expression in hamster and human pancreatic neoplasia",
abstract = "Cyclooxygenase-2 (COX-2) has been implicated in the development of gastrointestinal malignancies. The aim of the present study was to determine COX-2 expression/activity throughout stages of experimental and human pancreatic neoplasia. COX-2 immunohistochemistry was performed in pancreata of hamsters subjected to the carcinogen N-nitrosobis-(2-oxopropyl) amine (BOP) and in human pancreatic tumors. COX-2 activity was determined by prostaglandin E2 assay in tumor versus matched normal pancreatic tissues. The activity of the COX inhibitor sulindac was tested in the PC-1 hamster pancreatic cancer model. COX-2 expression was elevated in all pancreatic intraepithelial neoplasias (PanINs) and adenocarcinomas. In BOP-treated hamsters, there were significant progressive elevations in COX-2 expression throughout pancreatic tumorigenesis. In human samples, peak COX-2 expression occurred in PanIN2 lesions and remained moderately elevated in PanIN3 and adenocarcinoma tissues. COX-2 activity was significantly elevated in hamster and human pancreatic cancers compared to pair-matched normal pancreas. Furthermore, hamster pancreatic tumor engraftment/formation in the PC-1 hamster pancreatic cancer model was reduced 4.9-fold by oral administration of sulindac. Increased COX-2 expression is an early event in pancreatic carcinogeneses. The BOP-induced hamster carcinogenesis model is a representative model used to study the role of COX-2 in well-differentiated pancreatic tumorigenesis. COX inhibitors may have a role in preventing tumor engraftment/formation.",
keywords = "Chemical carcinogenesis, COX-2, Pancreatic neoplasms, PanIN, Sulindac",
author = "Crowell, {Pamela L.} and C. Schmidt and Michele Yip-Schneider and Savage, {Jesse J.} and Hertzler, {Dean A.} and Oscar Cummings",
year = "2006",
doi = "10.1593/neo.04700",
language = "English",
volume = "8",
pages = "437--445",
journal = "Neoplasia",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Cyclooxygenase-2 expression in hamster and human pancreatic neoplasia

AU - Crowell, Pamela L.

AU - Schmidt, C.

AU - Yip-Schneider, Michele

AU - Savage, Jesse J.

AU - Hertzler, Dean A.

AU - Cummings, Oscar

PY - 2006

Y1 - 2006

N2 - Cyclooxygenase-2 (COX-2) has been implicated in the development of gastrointestinal malignancies. The aim of the present study was to determine COX-2 expression/activity throughout stages of experimental and human pancreatic neoplasia. COX-2 immunohistochemistry was performed in pancreata of hamsters subjected to the carcinogen N-nitrosobis-(2-oxopropyl) amine (BOP) and in human pancreatic tumors. COX-2 activity was determined by prostaglandin E2 assay in tumor versus matched normal pancreatic tissues. The activity of the COX inhibitor sulindac was tested in the PC-1 hamster pancreatic cancer model. COX-2 expression was elevated in all pancreatic intraepithelial neoplasias (PanINs) and adenocarcinomas. In BOP-treated hamsters, there were significant progressive elevations in COX-2 expression throughout pancreatic tumorigenesis. In human samples, peak COX-2 expression occurred in PanIN2 lesions and remained moderately elevated in PanIN3 and adenocarcinoma tissues. COX-2 activity was significantly elevated in hamster and human pancreatic cancers compared to pair-matched normal pancreas. Furthermore, hamster pancreatic tumor engraftment/formation in the PC-1 hamster pancreatic cancer model was reduced 4.9-fold by oral administration of sulindac. Increased COX-2 expression is an early event in pancreatic carcinogeneses. The BOP-induced hamster carcinogenesis model is a representative model used to study the role of COX-2 in well-differentiated pancreatic tumorigenesis. COX inhibitors may have a role in preventing tumor engraftment/formation.

AB - Cyclooxygenase-2 (COX-2) has been implicated in the development of gastrointestinal malignancies. The aim of the present study was to determine COX-2 expression/activity throughout stages of experimental and human pancreatic neoplasia. COX-2 immunohistochemistry was performed in pancreata of hamsters subjected to the carcinogen N-nitrosobis-(2-oxopropyl) amine (BOP) and in human pancreatic tumors. COX-2 activity was determined by prostaglandin E2 assay in tumor versus matched normal pancreatic tissues. The activity of the COX inhibitor sulindac was tested in the PC-1 hamster pancreatic cancer model. COX-2 expression was elevated in all pancreatic intraepithelial neoplasias (PanINs) and adenocarcinomas. In BOP-treated hamsters, there were significant progressive elevations in COX-2 expression throughout pancreatic tumorigenesis. In human samples, peak COX-2 expression occurred in PanIN2 lesions and remained moderately elevated in PanIN3 and adenocarcinoma tissues. COX-2 activity was significantly elevated in hamster and human pancreatic cancers compared to pair-matched normal pancreas. Furthermore, hamster pancreatic tumor engraftment/formation in the PC-1 hamster pancreatic cancer model was reduced 4.9-fold by oral administration of sulindac. Increased COX-2 expression is an early event in pancreatic carcinogeneses. The BOP-induced hamster carcinogenesis model is a representative model used to study the role of COX-2 in well-differentiated pancreatic tumorigenesis. COX inhibitors may have a role in preventing tumor engraftment/formation.

KW - Chemical carcinogenesis

KW - COX-2

KW - Pancreatic neoplasms

KW - PanIN

KW - Sulindac

UR - http://www.scopus.com/inward/record.url?scp=33745833966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745833966&partnerID=8YFLogxK

U2 - 10.1593/neo.04700

DO - 10.1593/neo.04700

M3 - Article

VL - 8

SP - 437

EP - 445

JO - Neoplasia

JF - Neoplasia

SN - 1522-8002

IS - 6

ER -